Two NIDDK programs, one focused on Type 1 Diabetes (see NIH grant RFA here) and one focused on Obesity (see NIH grant RFA here) funded three different groups with the goal of developing and disseminating targeted mass spectrometry assays for the diagnosis and monitoring of Type 1 Diabetes and Obesity.  While the funding sources are separate, we felt there were obvious synergies in these efforts and formed TaMADOR with the goal of leveraging each other's capabilities and strengths.


Part of the project? Click HERE for internal resources (agendas, meeting logs, etc).

Type 1 Diabetes Assays

Quantifying Proteins in Plasma to Democratize Personalized Medicine for Patients with Type 1 Diabetes



Obesity Assays

Design and Validation of Easy-to-Adopt Mass Spectrometry Assays of Importance to Obesity



Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity


MSACL Workshop on the Development, Validation, and Implementation of Obesity and Diabetes Assays 2021-06-02

The NIDDK recently started a program for developing mass spectrometric assays for proteins and peptides of primary interest to the obesity and diabetes research community. These assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. Examples, of proteins and peptides that are of potential interest include insulin, glucagon, c-pepitide, glycated CD59, Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide, RBP4, myostatin, FGF21).

We will introduce the TaMADOR (Targeted Mass Spectrometric Assays for Diabetes and Obesity Research) program and discuss how we might proceed in developing, validating, and implementing MS assays of interest to the Obesity and Diabetes community.

Workshop on Thu Jun 03, 2021 from 10am to noon Pacific Time.

Register here at: https://msacl-org.zoom.us/meeting/register/tZArf-uhqz0jEtdLLDHrG8qUP7kMrUcwFyez

Announcing TaMADOR: A Collaborative Working Group for Targeted Mass Spectrometry Assays 2020-05-08

Two NIDDK programs, one focused on Type 1 Diabetes (https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-019.html) and one focused on Obesity (https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-001.html) are working together to develop and share quantitative protein assays. Andy Hoofnagle's lab at the University of Washington is working on Type 1 Diabetes. Jenny Van Eyk's and Wei-Jun Qian's labs at Cedars-Sinai and PNNL respectively are working on Obesity. To leverage each other's capabilities and strengths we have formed a working group that we call TaMADOR (Targeted Mass Spectrometry Assays for Diabetes and Obesity Research).